NO2475387T3 - - Google Patents
Info
- Publication number
- NO2475387T3 NO2475387T3 NO10815041A NO10815041A NO2475387T3 NO 2475387 T3 NO2475387 T3 NO 2475387T3 NO 10815041 A NO10815041 A NO 10815041A NO 10815041 A NO10815041 A NO 10815041A NO 2475387 T3 NO2475387 T3 NO 2475387T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/906—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
- G01N2333/90605—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4)
- G01N2333/90633—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3) in general
- G01N2333/90638—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3) in general with a definite EC number (1.4.3.-)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24040209P | 2009-09-08 | 2009-09-08 | |
| US32303210P | 2010-04-12 | 2010-04-12 | |
| PCT/FI2010/050689 WO2011029996A1 (en) | 2009-09-08 | 2010-09-07 | Use of vap-1 inhibitors for treating fibrotic conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2475387T3 true NO2475387T3 (ru) | 2018-03-31 |
Family
ID=43732037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO10815041A NO2475387T3 (ru) | 2009-09-08 | 2010-09-07 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9795671B2 (ru) |
| EP (1) | EP2475387B1 (ru) |
| JP (3) | JP6009355B2 (ru) |
| KR (2) | KR101837117B1 (ru) |
| CN (2) | CN107661500A (ru) |
| AU (1) | AU2010294123B2 (ru) |
| CA (1) | CA2773218C (ru) |
| CY (1) | CY1119867T1 (ru) |
| DK (1) | DK2475387T3 (ru) |
| ES (1) | ES2657943T3 (ru) |
| HR (1) | HRP20180131T1 (ru) |
| HU (1) | HUE035890T2 (ru) |
| IL (1) | IL218535A (ru) |
| LT (1) | LT2475387T (ru) |
| ME (1) | ME02999B (ru) |
| NO (1) | NO2475387T3 (ru) |
| NZ (3) | NZ706740A (ru) |
| PL (1) | PL2475387T3 (ru) |
| PT (1) | PT2475387T (ru) |
| RS (1) | RS56809B1 (ru) |
| RU (2) | RU2667963C1 (ru) |
| SG (1) | SG179012A1 (ru) |
| SI (1) | SI2475387T1 (ru) |
| UA (1) | UA112154C2 (ru) |
| WO (1) | WO2011029996A1 (ru) |
| ZA (1) | ZA201202515B (ru) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA112154C2 (uk) * | 2009-09-08 | 2016-08-10 | Біоті Терапіс Корп. | Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів |
| JP5953035B2 (ja) * | 2011-11-28 | 2016-07-13 | 学校法人慶應義塾 | 病理診断支援装置、病理診断支援方法、及び病理診断支援プログラム |
| SG11201406948PA (en) | 2012-05-02 | 2014-11-27 | Boehringer Ingelheim Int | Substituted 3-haloallylamine inhibitors of ssao and uses thereof |
| WO2014024820A1 (ja) * | 2012-08-06 | 2014-02-13 | 塩野義製薬株式会社 | 新規慢性腎臓病治療用医薬組成物及び新規慢性腎臓病治療薬のスクリーニング方法 |
| KR102205845B1 (ko) | 2013-10-28 | 2021-01-22 | 삼성전자주식회사 | 입자에 기반한 모델링 방법 및 장치 |
| WO2015189534A1 (en) * | 2014-06-12 | 2015-12-17 | Proximagen Limited | Vap-1 inhibitors for treating muscular dystrophy |
| JP2018080114A (ja) * | 2015-05-29 | 2018-05-24 | 株式会社アールテック・ウエノ | 抗ヒトｖａｐ−１モノクローナル抗体 |
| KR102340352B1 (ko) * | 2017-06-27 | 2021-12-21 | 주식회사 뉴라클사이언스 | 섬유증의 치료를 위한 항-fam19a5 항체의 용도 |
| WO2023164548A1 (en) * | 2022-02-23 | 2023-08-31 | Yale University | Il-6 inhibitor as treatment for nephropathy |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4997854A (en) * | 1989-08-25 | 1991-03-05 | Trustees Of Boston University | Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates |
| US5580780A (en) | 1992-06-09 | 1996-12-03 | Jalkanen; Sirpa | Vascular adhesion protein-(VAP-1) and VAP-1-specific antibodies |
| EP0979271A1 (en) * | 1997-05-23 | 2000-02-16 | Biotie Therapies Ltd. | Vascular adhesion protein-1 having amine oxidase activity |
| WO2002002541A2 (en) | 2000-07-05 | 2002-01-10 | Biotie Therapies Corp. | Inhibitors of copper-containing amine oxidases |
| WO2002038153A1 (en) | 2000-11-09 | 2002-05-16 | Biovitrum Ab | New use of 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine derivatives |
| WO2002053161A1 (en) * | 2000-12-29 | 2002-07-11 | Alteon, Inc. | Method for treating fibrotic diseases or other indications |
| US6982286B2 (en) | 2001-07-12 | 2006-01-03 | Biotie Therapies Corp. | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
| FI20020807A0 (fi) | 2002-04-29 | 2002-04-29 | Biotie Therapies Oyj | Uusia humanisoituja anti-VAP-1 monoklonaalisia vasta-aineita |
| EP1587800A1 (en) | 2003-01-27 | 2005-10-26 | Astellas Pharma Inc. | Thiazole derivatives and their use as vap-1 inhibitors |
| JP4758337B2 (ja) | 2003-03-31 | 2011-08-24 | 株式会社アールテック・ウエノ | 血管透過性亢進疾患を治療する方法 |
| JP2007501802A (ja) | 2003-08-08 | 2007-02-01 | ラ ホヤ ファーマシューティカル カンパニー | 疾患の処置に有用な、セミカルバジド感受性アミンオキシダーゼ（ｓｓａｏ）およびｖａｐ−１媒介性接着のインヒビター |
| WO2005072738A1 (en) | 2004-01-30 | 2005-08-11 | Faron Pharmaceuticals Oy | Compositions useful especially for treatment or prevention of metabolic syndrome |
| FI20040270A0 (fi) | 2004-02-20 | 2004-02-20 | Biotie Therapies Oyj | Kuparia sisältävien amiinioksidaasien imhibiittoreina käyttökelpoiset hydratsinoalkoholijohdannaiset |
| AU2005216955A1 (en) | 2004-02-25 | 2005-09-09 | La Jolla Pharmaceutical Company | Amines and amides for the treatment of diseases |
| KR101206319B1 (ko) | 2004-03-18 | 2012-11-29 | 가부시키가이샤 아루떼꾸 우에노 | 티아졸 유도체를 포함하는 수성 조성물 |
| CA2575411A1 (en) | 2004-07-27 | 2006-02-02 | Astellas Pharma Inc. | Thiazole derivatives having vap-1 inhibitory activity |
| US20080269282A1 (en) | 2004-08-02 | 2008-10-30 | Genmedica Therapeutics Sl | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof |
| EP1791835A2 (en) | 2004-09-09 | 2007-06-06 | Astellas Pharma Inc. | Thiazole derivatives having vap-1 inhibitory activity |
| WO2006094201A2 (en) | 2005-03-02 | 2006-09-08 | La Jolla Pharmaceutical Company | Semicarbazide-sensitive amide oxidase inhibitors |
| WO2007005737A2 (en) | 2005-07-01 | 2007-01-11 | Case Western Reserve University | Amine oxidase inhibitors |
| US20070066646A1 (en) | 2005-08-02 | 2007-03-22 | Genmedica Therapeutics Sl | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof |
| US20080058922A1 (en) * | 2006-08-31 | 2008-03-06 | Cardiac Pacemakers, Inc. | Methods and devices employing vap-1 inhibitors |
| FI20075278A0 (fi) * | 2007-04-20 | 2007-04-20 | Biotie Therapies Corp | Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet |
| WO2009055002A1 (en) | 2007-10-24 | 2009-04-30 | La Jolla Pharmaceutical Company | Combined inhibitors of cyclooxygenase and semicarbazide-sensitive amine oxidase (ssao) (vascular adhesion protein, vap-1) |
| EP2222160B1 (en) | 2007-11-21 | 2015-03-18 | Pharmaxis Ltd. | Haloallylamine inhibitors of ssao/vap-1 and uses therefor |
| TWI437986B (zh) * | 2008-01-31 | 2014-05-21 | R Tech Ueno Ltd | 噻唑衍生物及使用該衍生物作為ｖａｐ－１抑制劑之用途 |
| TWI490214B (zh) | 2008-05-30 | 2015-07-01 | 艾德克 上野股份有限公司 | 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途 |
| HUP0800498A2 (en) | 2008-08-06 | 2010-03-29 | Semmelweis Egyetem | Use of dihydralazine for the preparation of medicaments for treatment of diseases related to ssao level |
| HUE025381T2 (en) | 2008-09-11 | 2016-02-29 | Pecsi Tudomanyegyetem | Compounds for the inhibition of SSAO / VAP-1 and their use for the treatment and prevention of diseases |
| CA2737527C (en) | 2008-09-16 | 2015-12-29 | Proximagen Limited | 4,5,6,7-tetrahydroimidazo[4,5-c]pyridine compounds useful as inhibitors of ssao activity |
| ES2403633T3 (es) | 2008-12-04 | 2013-05-20 | Proximagen Limited | Compuestos de imidazopiridina |
| UA112154C2 (uk) * | 2009-09-08 | 2016-08-10 | Біоті Терапіс Корп. | Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів |
-
2010
- 2010-07-09 UA UAA201204308A patent/UA112154C2/uk unknown
- 2010-09-07 SG SG2012015772A patent/SG179012A1/en unknown
- 2010-09-07 NZ NZ706740A patent/NZ706740A/en not_active IP Right Cessation
- 2010-09-07 CN CN201710879422.4A patent/CN107661500A/zh active Pending
- 2010-09-07 KR KR1020127009075A patent/KR101837117B1/ko active IP Right Grant
- 2010-09-07 AU AU2010294123A patent/AU2010294123B2/en not_active Ceased
- 2010-09-07 RU RU2016107043A patent/RU2667963C1/ru active
- 2010-09-07 SI SI201031624T patent/SI2475387T1/en unknown
- 2010-09-07 PL PL10815041T patent/PL2475387T3/pl unknown
- 2010-09-07 DK DK10815041.8T patent/DK2475387T3/en active
- 2010-09-07 JP JP2012528399A patent/JP6009355B2/ja not_active Expired - Fee Related
- 2010-09-07 KR KR1020187006357A patent/KR20180026808A/ko not_active IP Right Cessation
- 2010-09-07 NO NO10815041A patent/NO2475387T3/no unknown
- 2010-09-07 RU RU2012113561/15A patent/RU2580626C2/ru active
- 2010-09-07 ES ES10815041.8T patent/ES2657943T3/es active Active
- 2010-09-07 PT PT108150418T patent/PT2475387T/pt unknown
- 2010-09-07 NZ NZ598920A patent/NZ598920A/en not_active IP Right Cessation
- 2010-09-07 EP EP10815041.8A patent/EP2475387B1/en active Active
- 2010-09-07 NZ NZ61643210A patent/NZ616432A/en not_active IP Right Cessation
- 2010-09-07 CN CN2010800503481A patent/CN102740886A/zh active Pending
- 2010-09-07 WO PCT/FI2010/050689 patent/WO2011029996A1/en active Application Filing
- 2010-09-07 RS RS20180101A patent/RS56809B1/sr unknown
- 2010-09-07 LT LTEP10815041.8T patent/LT2475387T/lt unknown
- 2010-09-07 CA CA2773218A patent/CA2773218C/en not_active Expired - Fee Related
- 2010-09-07 HU HUE10815041A patent/HUE035890T2/en unknown
- 2010-09-07 US US13/395,029 patent/US9795671B2/en active Active
-
2012
- 2012-03-07 IL IL218535A patent/IL218535A/en active IP Right Grant
- 2012-04-05 ZA ZA2012/02515A patent/ZA201202515B/en unknown
-
2016
- 2016-01-08 JP JP2016003089A patent/JP6290940B2/ja not_active Expired - Fee Related
-
2017
- 2017-09-21 US US15/711,828 patent/US10576148B2/en not_active Expired - Fee Related
-
2018
- 2018-01-23 HR HRP20180131TT patent/HRP20180131T1/hr unknown
- 2018-01-31 CY CY20181100116T patent/CY1119867T1/el unknown
- 2018-02-08 JP JP2018020789A patent/JP2018104445A/ja active Pending
- 2018-02-28 ME MEP-2018-21A patent/ME02999B/me unknown